NASDAQ:VTVT

vTv Therapeutics - VTVT Stock Forecast, Price & News

$0.90

0.00 (0.00%)

(As of 09/27/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.88
▼
$0.92
50-Day Range: $0.71
▼
$1.37
52-Week Range: $0.38
▼
$1.76

Volume: 71,633 shs
Average Volume: 97,734 shs
Market Capitalization: $94.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.50

vTv Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 288.9% Upside
$3.50 Price Target
Short Interest: Healthy
4.50% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.23
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.24) to ($0.30) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars

Medical Sector

922nd out of 1,071 stocks

Pharmaceutical Preparations Industry

444th out of 531 stocks

3.5

Analyst's Opinion

Consensus Rating
vTv Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.50, vTv Therapeutics has a forecasted upside of 288.9% from its current price of $0.90.
Amount of Analyst Coverage
vTv Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.50% of the float of vTv Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
vTv Therapeutics has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in vTv Therapeutics has recently decreased by 3.15%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
vTv Therapeutics does not currently pay a dividend.
Dividend Growth
vTv Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VTVT.

1.8

News and Social Media Coverage

News Sentiment
vTv Therapeutics has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for vTv Therapeutics this week, compared to 0 articles on an average week.
MarketBeat Follows
Only 1 people have added vTv Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, vTv Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.70% of the stock of vTv Therapeutics is held by insiders.
Percentage Held by Institutions
Only 7.35% of the stock of vTv Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for vTv Therapeutics are expected to decrease in the coming year, from ($0.24) to ($0.30) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of vTv Therapeutics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of vTv Therapeutics is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About vTv Therapeutics (NASDAQ:VTVT) Stock

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator for renal diseases through partnerships with pharmaceutical partners. The company has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.

Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Stock News Headlines

September 23, 2022 | finance.yahoo.com

vTv Therapeutics (NASDAQ:VTVT shareholders incur further losses as stock declines 17% this week, taking five-year losses to 84%

September 23, 2022 | americanbankingnews.com

vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com

September 22, 2022 | seekingalpha.com

VTVT vTv Therapeutics Inc.

August 19, 2022 | finance.yahoo.com

This Diabetes Drug's 'Licensing Opportunity Is Underappreciated,' Analyst Says

August 19, 2022 | bizjournals.com

After third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 million net loss in Q2

August 18, 2022 | finance.yahoo.com

After third leadership change in less than a year, vTv Therapeutics Inc. reports $3.2 net loss in Q2

August 16, 2022 | finance.yahoo.com

vTv Therapeutics Announces 2022 Second Quarter Financial Results and Provides Corporate Update

August 13, 2022 | finance.yahoo.com

What You Need To Know About vTv Therapeutics Inc.'s (NASDAQ:VTVT) Investor Composition

August 9, 2022 | finance.yahoo.com

Months after celebrating its first exit, CinRx invests $10M in newest portfolio company

July 27, 2022 | finance.yahoo.com

vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer

July 25, 2022 | finance.yahoo.com

vTv Therapeutics Shares Jump On Equity Investment

July 25, 2022 | finance.yahoo.com

vTv Therapeutics Announces Investment by CinRx Pharma

June 17, 2022 | msn.com

vTv Therapeutics Earnings Perspective: Return On Capital Employed

June 4, 2022 | finance.yahoo.com

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

June 3, 2022 | nz.finance.yahoo.com

Aravive Appoints Rudy Howard as Chief Financial Officer

June 1, 2022 | investorplace.com

vTv Therapeutics (VTVT) Stock Surges 41% on Major Investment News

June 1, 2022 | seekingalpha.com

vTv Therapeutics surges on licensing deal for diabetes candidate

June 1, 2022 | finance.yahoo.com

vTv Therapeutics Announces Investment by and Entry into Collaboration and License Agreement with affiliates of G42 Healthcare

May 27, 2022 | finance.yahoo.com

3 Oversold Biotech Stocks to Buy Now

May 14, 2022 | seekingalpha.com

vTv Therapeutics GAAP EPS of -$0.10, revenue of $2M

May 12, 2022 | finance.yahoo.com

vTv Therapeutics Announces 2022 First Quarter Financial Results and Provides Corporate Update

April 1, 2022 | bizjournals.com

vTv Therapeutics reports $17.6M loss in 2021, names new acting CEO

March 31, 2022 | finance.yahoo.com

vTv Therapeutics (NASDAQ:VTVT) investors are sitting on a loss of 89% if they invested five years ago

March 31, 2022 | benzinga.com

vTv Therapeutics's Return On Capital Employed Overview

March 29, 2022 | finance.yahoo.com

vTv Therapeutics Announces 2021 fourth Quarter and Full Year Financial Results and Provides Corporate Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Company Calendar

Last Earnings: 8/15/2022
Today: 9/28/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VTVT
CUSIP: N/A
CIK: 1641489
Web: www.vtvtherapeutics.com
Phone: (336) 841-0300
Fax: 336-841-0310
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.50
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +288.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-12,990,000.00
Net Margins: -364.61%
Pretax Margin: -481.53%
Return on Equity: N/A
Return on Assets: -57.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.12
Quick Ratio: 3.12

Sales & Book Value

Annual Sales: $4.01 million
Price / Sales: 23.47
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.11) per share
Price / Book: -8.18

Miscellaneous

Outstanding Shares: 104,580,000
Free Float: 103,845,000
Market Cap: $94.12 million
Optionable: Not Optionable
Beta: -1.39

Key Executives

Ms. Deepa Prasad (Age 42)
Strategic Advisor
Comp: $667.13k

Mr. Paul J. Sekhri M.Sc. (Age 64)
MSc, CEO, Pres & Director

Mr. Barry Brown (Age 61)
Chief Accounting Officer

Dr. Carmen Valcarce Ph.D.
Chief Scientific Officer & Exec. VP

Vanessa McDade
Chief Admin. Officer

Mr. David M. Lambert III
Sr. VP & Gen. Counsel

Mr. Richard S. Nelson (Age 52)
Exec. VP of Corp. Devel. & Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VTVT Stock - Frequently Asked Questions

Should I buy or sell vTv Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTVT shares.
View VTVT analyst ratings or view top-rated stocks.
What is vTv Therapeutics' stock price forecast for 2022?: 2 equities research analysts have issued twelve-month price objectives for vTv Therapeutics' stock. Their VTVT share price forecasts range from $2.00 to $5.00. On average, they predict the company's share price to reach $3.50 in the next year. This suggests a possible upside of 288.9% from the stock's current price.
View analysts price targets for VTVT or view top-rated stocks among Wall Street analysts.
How have VTVT shares performed in 2022?: vTv Therapeutics' stock was trading at $0.9950 on January 1st, 2022. Since then, VTVT shares have decreased by 9.5% and is now trading at $0.90.
View the best growth stocks for 2022 here.
When is vTv Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our VTVT earnings forecast.
How were vTv Therapeutics' earnings last quarter?: vTv Therapeutics Inc. (NASDAQ:VTVT) issued its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.10) by $0.06. The biotechnology company had revenue of $0.01 million for the quarter.
What other stocks do shareholders of vTv Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?: (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.
What is vTv Therapeutics' stock symbol?: vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."
Who are vTv Therapeutics' major shareholders?: vTv Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (0.23%), Millennium Management LLC (0.15%), Prudential Financial Inc. (0.04%) and Simon Quick Advisors LLC (0.03%). Insiders that own company stock include Hersh Kozlov and Ronald O Perelman.
View institutional ownership trends.
How do I buy shares of vTv Therapeutics?: Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is vTv Therapeutics' stock price today?: One share of VTVT stock can currently be purchased for approximately $0.90.
How much money does vTv Therapeutics make?: vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $94.12 million and generates $4.01 million in revenue each year. The biotechnology company earns $-12,990,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.
How can I contact vTv Therapeutics?: vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310.

This page (NASDAQ:VTVT) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

vTv Therapeutics - VTVT Stock Forecast, Price & News

vTv Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month